

![]() |
A novel µ-conopeptide, CnIIIC, exerts potent and preferential inhibition of NaV1.2/1.4 channels and blocks neuronal nicotinic acetylcholine receptors |
|
Authors | ![]() | |
Published in | British Journal of Pharmacology. 2012, vol. 166, no. 5, p. 1654-68 | |
Abstract | The µ-conopeptide family is defined by its ability to block voltage-gated sodium channels (VGSCs), a property that can be used for the development of myorelaxants and analgesics. We characterized the pharmacology of a new µ-conopeptide (µ-CnIIIC) on a range of preparations and molecular targets to assess its potential as a myorelaxant. | |
Identifiers | PMID: 22229737 | |
Full text | ||
Structures | ||
Research group | HIV (835) | |
Citation (ISO format) | FAVREAU, Philippe et al. A novel µ-conopeptide, CnIIIC, exerts potent and preferential inhibition of NaV1.2/1.4 channels and blocks neuronal nicotinic acetylcholine receptors. In: British Journal of Pharmacology, 2012, vol. 166, n° 5, p. 1654-68. doi: 10.1111/j.1476-5381.2012.01837.x https://archive-ouverte.unige.ch/unige:23511 |